… genital warts within a large US commercially insured, geographically dispersed population.
… Genital warts cases were identified using a methodology previously described by Insinga et …

… care and reducing population-level costs. This study is limited by its restriction to a commercially
insured population and an inability to assess relative effectiveness of wart treatments. …

… associated with treating genital warts in the USA among a commercially insured population.
… -year costs associated with treating genital warts in the USA among a commercially insured …

… insurance within a given year. We derived anogenital wart diagnoses from a diagnosis of
condyloma acuminata, or either a less specific viral wart diagnosis or genital wart medication …

… The incidence and healthcare cost of genital warts in a commercially insured population in
the United States. In: Abstract Book of the 24th International Papillomavirus Conference and …

… According to our definitions, we identified a total of 39 493 people with 43 586 episodes
of genital warts from 1998 to 2006. The majority of these patients were identified from the …

… vaccine studies from around the world through 2016 reported high HPV vaccine impact on
reducing anogenital warts. Significantly reduced risks of anogenital warts were observed for …

… or Italian using the following search terms: (genital warts OR genital wart OR anogenital
warts OR anogenital wart OR condyloma* OR genital verruca*) AND (prevalence OR incidence …

… We also thank GPRD for providing the data on genital warts in general practice for this
study and all the practices that contribute to the GPRD. We are grateful to Julia Stowe and the …

… Genital warts are caused by HPV types 6 and 11, which are responsible for more than 90%
of cases. In Italy, it has been estimated that the prevalence of genital warts in … of genital warts, …